1st Quarter - Report

THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER for THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$900,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report (this page) May 1, 2025 $900,000 Replaced
1st Quarter - Amendment May 8, 2026 $90,000 Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

All legislation related to Medicare site of service payment policy changes; the Cassidy Hassan Senate framework for hospital site neutral payments; Issues related to Medicare reimbursements for cancer services; Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; Medicare Advantage preauthorization; Medicare Advantage access issues; Cuts to services related to cancer diagnosis and treatment; Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products; Policies related to the value of cancer care and initiatives that bend the cost curve.

LobbyistCovered position, as disclosed
EDWARD MILLER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

Issues related to the President's upcoming federal budget request; Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research. Funding for NIH and NCI. Issues related to the reorganization of HHS and its underlying agencies: NIH, CDC, CMS, and FDA; impact of executive order on NIH indirect costs and what it means for the institution and the biomedical research space as a whole; the future of ARPA-H; federal grant recisions

LobbyistCovered position, as disclosed
EDWARD MILLER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Government Issues GOV

Issues related to the reorganization of HHS and its underlying agencies: NIH, CDC, CMS, and FDA; impact of executive order on NIH indirect costs and what it means for the institution and the biomedical research space as a whole; the future of ARPA-H; federal grant terminations; DOGE information website on grant recipients; the future of global health programs

LobbyistCovered position, as disclosed
EDWARD MILLER —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.